310 related articles for article (PubMed ID: 33721375)
21. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
22. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
El-Ghammaz AMS; Gadallah HA; Kamal G; Maher MM; Mohamad MA
Clin Exp Med; 2018 Nov; 18(4):505-512. PubMed ID: 29876769
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
24. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract][Full Text] [Related]
25. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
26. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
Liu XL; He P; Lei J; Zou LX; Peng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
[TBL] [Abstract][Full Text] [Related]
28. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
[TBL] [Abstract][Full Text] [Related]
29. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
30. Targeting the programmed death-1 pathway in lymphoid neoplasms.
Ok CY; Young KH
Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
32. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
33. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
34. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
35. Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis.
Cai L; Zhang C; Wu J; Zhou W; Chen T
Clin Immunol; 2021 Aug; 229():108800. PubMed ID: 34289424
[TBL] [Abstract][Full Text] [Related]
36. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
38. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Khan M; Zhao Z; Arooj S; Fu Y; Liao G
Front Immunol; 2020; 11():587460. PubMed ID: 33329567
[TBL] [Abstract][Full Text] [Related]
39. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
Jalali S; Price-Troska T; Paludo J; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Ansell SM
Blood Adv; 2018 Aug; 2(15):1985-1997. PubMed ID: 30104397
[TBL] [Abstract][Full Text] [Related]
40. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]